Global Cell Free DNA Isolation and Extraction Market Report Analysis

A quick peek into the report

Market Overview

Cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026.

Biomarker play an important role in development of translational medicine, which facilitates translation of basic research into medical advances. In line with this, most pharmaceutical and biotechnology companies are committing to associate their therapeutic drugs with diagnostic assays to monitor the drug response as number of biomarkers are directly associated with drugs. For instance, Thermo Fisher Scientific in collaboration with Novartis AG, Pfizer Inc. and GlaxoSmithKline Plc. is developing multi-market universal next-generation sequencing for multiple companion diagnostic programs, which will help pharma companies to match cancer patients with specific drug candidate

Early detection of cancer requires suitable diagnostic procedures to screen asymptomatic population which is on average risk of cancer, particularly for breast cancer, cervical cancers, colon cancers and melanoma. Increasing awareness of early signs and symptoms of cancer among physicians and other healthcare professionals as well as among general population. Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment. Clinical trials are also funded by governments to support companies in developing effective diagnostic tests for cancer. The cell-free DNA isolation and extraction market drivers includes inclusion of cancer screening tests in national cancer screening programs, increasing discretionary funding for cancer research, associating drugs with diagnostic assays, constantly growing list of cancer biomarkers, exploring next-generation sequencing techniques for cancer diagnostics and others. Market restrains includes lack of standardization and appropriate controls of cell free DNA kits, insurance coverage and reimbursement issues and enormous R&D investment with no therapeutic result.

The global cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026, aided by the rising demand for non-invasive prenatal testing among high risk pregnant women and increased demand for liquid biopsy. North America is the leading contributor to the global cell free DNA isolation and extraction market, in terms of both, volume and revenue. The contribution of North America to the global cell free DNA isolation and extraction market was volume and valued to be approximately 59% and 61% in 2016, respectively. However, Asia Pacific is expected to grow, by volume, at an impressive 21.15% CAGR during the forecast period. The extraction kits hold the largest share of the total cfDNA extraction/isolation market and growing at a double digit CAGR. Furthermore, with magnetic bead-based kits, proteinase and heat treatment are unnecessary, enabling all the processes to be conducted at room temperature. As compared to traditional cfDNA extraction methods, there is also a significant reduction in processing and hands-on time.

Among the applications, non-invasive prenatal testing (NIPT) leads the cfDNA extraction/isolation market share. In 2016, the NIPT segment accounted for 72% of the total market. However, the market share of NIPT segment is expected to decrease substantially during the forecast period owing high market penetration rate of cfDNA technology in the cancer diagnostic and screening application. In 2016, next generation sequencing was the most used downstream quantification technique for cfDNA and accounted for 71% of the total sample processing share and is expected to remain the leading quantification technique in 2026.

This market intelligence report provides a multidimensional view of the global cell free DNA isolation and extraction market in terms of market size and growth potential. This research report aims at answering various aspects of the global cell free DNA isolation and extraction market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansions as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales, and manufacturers, and trend analysis by segments and demand analysis by geographical regions.

The report also profiles companies including several key players, such as Agilent Technologies, Inc., Berry Genomics, BGI Diagnostics, BioCAT GmbH, F. Hoffmann-La Roche AG, GATC Biotech AG., Illumina, Inc., Laboratory Corporation of America, LifeCodexx AG, Merck KGaA, Natera Inc., NIPD Genetics, Norgen Biotek Corp., PreAnalytiX GmbH, Premaitha Health Plc, QIAGEN, Quest Diagnostics, SeraCare Life Sciences, Inc., STRATEC Biomedical AG, Thermo Fisher Scientific, AccuBioMed, Aline Biosciences, BioChain, Bioo Scientific Corporation, COVARIS, INC., Epigentek Group Inc., NeoGenStar LLC, Omega Bio-tek, Inc, Promega Corporation, System Biosciences, LLC., and STRECK, INC., among others.

Key Questions Answered in this Report

What are the major market drivers, challenges and opportunities in the Cell-free DNA testing market?

Report Description

Cell free DNA isolation and extraction market is anticipated to grow over $442.8 Million with 14,638.3 Thousand units by 2026.

Cell-free DNA are non-encapsulated DNA that enters the bloodstream during apoptosis or necrosis. This cell-free DNA is cleared by macrophages during normal body functioning, but overproduction of cells during cancer produces extra cfDNA in the blood. The CfDNA are found in blood, plasma, serum, or other body fluids and holds clinical significance in diagnosis, monitoring, and detection of various non-invasive diseases. The cfDNA is a screening method for tumors and other fetal DNA studies, they are challenging to extract as they are found in small quantities, and so reliable and consistent methods are required to isolate the less abundant cell-free DNA with higher sensitivity as they have a half-life of about two hours. The global cfDNA extraction and isolation industry is a multi-billion-dollar market which consists of multitudinous companies involved in the development of cfDNA extraction/isolation kits and automated instruments based on various sequencing platforms such as NGS and PCR to bolster the increasing demand for non-invasive screening tests and procedures.

cfDNA extraction and isolation products include extraction/isolation kit, automated instruments, and other consumables to improve the overall non-invasive screening process efficiency. Cell-free DNA testing is a new and efficient technology in which free-flowing DNA fragments from a liquid sample such as saliva, urine, and blood from patients are analyzed to screen a condition or disease. Cell-free DNA testing is essential solutions for the medical diagnostic companies that are facing increasing level of demand for high productivity and cost reduction. The recent advances in Cell-free DNA testing have paved the way for the development of multiple advanced technologies to aid in the battle against cancer and various other diseases including genetic and infectious diseases. The advent of screening procedures such as NIPT and liquid biopsy with improved efficiency of screening results are the most prominent factors facilitating the growth of Cell-free DNA testing in the medical diagnostic industry. Furthermore, these advanced testing procedures have also enabled the companies in the medical diagnostic industry to meet the regulatory compliance as well as manage their profit margins and remain competitive in the market.

The purpose of this study is to gain a holistic view of the Cell-free DNA testing market in terms of various influencing factors, such as recent trends and technological advancements. The scope of this report constitutes an in-depth study of the global Cell-free DNA testing market, including a thorough analysis of the products across different regions. The market has been segmented into ‘product’, ‘platform’, ‘application ‘and ‘regions’. The report presents the reader with an opportunity to unlock comprehensive insights concerning the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global Cell-free DNA testing market with the help of the key factors driving the market, restraints that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities and challenges) and industry analysis as well.

The research study considers the market share analysis for a comprehensive understanding of the global Cell-free DNA testing market and assesses the factors governing the same. Growth share matrix and detailed pricing analysis have been included in the report. The market by region has been further sub-segmented into various countries, and in each sub-segment, the key market trends, list of the key players, and the recent developments that have taken place have been discussed.

The key players who have been contributing significantly to the Cell-free DNA testing market include Agilent Technologies, Inc., Berry Genomics, BGI Diagnostics, BioCAT GmbH, F. Hoffmann-La Roche AG, GATC Biotech AG., Illumina, Inc., Laboratory Corporation of America, LifeCodexx AG, Merck KGaA, Natera Inc., NIPD Genetics, Norgen Biotek Corp., PreAnalytiX GmbH, Premaitha Health Plc, QIAGEN, Quest Diagnostics, SeraCare Life Sciences, Inc., STRATEC Biomedical AG, Thermo Fisher Scientific, AccuBioMed, Aline Biosciences, BioChain, Bioo Scientific Corporation, COVARIS, INC., Epigentek Group Inc., NeoGenStar LLC, Omega Bio-tek, Inc, Promega Corporation, System Biosciences, LLC., and STRECK, INC., among others.

Request a Sample

1.1   Introduction
1.2   Early Discovery and Applications of cfDNA
1.3   Properties of cfDNA
1.4   Biological Role of cfDNA
1.5   Extraction of Circulating cfDNA
1.6   Application of Circulating cfDNA
1.7   Addressable Market Size and Growth Potential
1.8   Recent Historical Trends 2013-2016 (Parent Market: Genomics)
1.9   Recent Historical Trends 2013-2016 (cfDNA)

2.1   Promoting and Inhibiting Factors of cfDNA Market Growth
2.2   Market Drivers
2.3   Market Restraints
2.4   Market Opportunities

3.1   Key Develoments and Stratgies
3.2   Market Share Analysis by Company (2015 and 2016)
3.3   Value Chain Analysis

4.1 cfDNA Extraction Kits Pricing Analysis

5.1   Analysis
5.2   Cell Free DNA Extraction and Isolation Kits
5.3   Cell Free DNA Automated Instruments
5.4   Consumables

6.1   Introduction
6.2   Next Generation Sequencing
6.3   Polymerase Chain Reaction (PCR)
6.4   Others

7.1   Overview
7.2   Non-Invasive Prenatal Testing (NIPT)
7.3   Oncology
7.4   Transplant Rejection and Other Disease Condition
7.5   Others

8.1   Overview
8.2   North America
8.2.1   U.S.
8.2.2   Canada
8.3   Europe
8.3.1   Germany
8.3.2   France
8.3.3   U.K.
8.3.4   Italy
8.3.5   Spain
8.3.6   Denmarrk
8.3.7   Others
8.4   Asia Pacific
8.4.1   China
8.4.2   India
8.4.3   Singapore
8.4.4   Japan
8.4.5   Others
8.5   Latin America
8.5.1   Brazil
8.5.2   Mexico
8.5.3   Others
8.6   Rest of the World

9.1   Overview
9.2   Agilent Technologies, Inc.
9.3   AccuBioMed
9.4   Aline Biosciences
9.5   Berry Genomics
9.6   BioChain
9.7   Bioo Scientific Corporation
9.8   BGI Diagnostics
9.9   BioCAT GmbH
9.1   Epigentek Group Inc.
9.11   F. Hoffmann-La Roche AG
9.12   GATC Biotech AG.
9.13   Illumina, Inc.
9.14   Laboratory Corporation of America
9.15   LifeCodexx AG
9.16   Merck KGaA
9.17   Natera Inc.
9.18   NIPD Genetics
9.19   Norgen Biotek Corp
9.2   PreAnalytiX GmbH
9.21   Premaitha Health Plc
9.22   GATC Biotech AG.
9.23   Illumina, Inc.
9.24   Laboratory Corporation of America
9.25   QIAGEN
9.26   Quest Diagnostics
9.27   SeraCare Life Sciences, Inc.
9.28   STRATEC Biomedical AG
9.29   Thermo Fisher Scientific
9.3   NeoGenStar LLC
9.31   Omega Bio-tek, Inc
9.32   Promega Corporation
9.33   System Biosciences, LLC.
9.34   STRECK, INC.

10.1   Scope of the Report
10.2   Global Cell Free DNA Extraction and Isolation Market Segmentation
10.3   Research Methodology
10.3.1   Primary Research
10.3.2   Secondary Research
10.3.3   Key Data Points from Primary Sources
10.3.4   Key Data Points from Secondary Sources
10.3.5   Data Triangulation
10.3.6   Top-Down Approach (Segment wise Analysis)
10.3.7   Bottom-Up Approach (Segmental Analysis)
10.4   Assumptions and Limitations
10.5   Data and Prediction Modelling

1   Global cfDNA Extraction/Isolation Market
2   Advanced Technologies Employed for Circulating cell-free DNA
3   Market Share Analysis
4   cfDNA Extraction Kits Pricing Analysis
5   Global cfDNA Extraction/Isolation Market by Product ($Million)
6   By Product : Extraction/Isolation Kits: Key Players
7   List of Some Commercially Available Isolation Kits
8   Sales of Key Isolation Kits ($Million)
9   cfDNA Extraction/Isolation Kits Market by Method ($Million)
10   cfDNA Extraction/Isolation Kits Market by Method (Sample Processed, In Thousand Units)
11   By Product : Automated Instruments: Key Players
12   By Product : Consumables: Key Players
13   Product Analysis
14   Global cfDNA Extraction/Isolation Market by Platform ($Million)
15   Global cfDNA Extraction/Isolation Market by Platform (Sample Volume in Thousand)
16   Comparison between Next Generation Sequencing (NGS) and Polymerase Chain Reaction (dPCR)
17   Global cfDNA Extraction/Isolation Market by Application ($Million)
18   Global cfDNA Extraction/Isolation Market by Application (Sample Volume in Thousand)
19   Growth Share Matrix by cfDNA NIPT Test Providers
20   Global cfDNA Extraction/Isolation Market by Region ($Million)
21   Global cfDNA Extraction/Isolation Market by Region (Sample Volume in Thousand)
22   Key Players of North America
23   Key Players of Europe
24   Key Players of Asia Pacific
25   Key Players of Latin America and RoW
26   Latin America and RoW Market
27   List of Qiagen products for cfDNA
28   Thermo Fisher Scientific: Product Portfolio

1   Global cfDNA Extraction and Isolation Market, 2016 and 2026
2   Global cfDNA Extraction and Isolation Market Value & Forecast, 2016–2026 (US$ Million)
3   Global cfDNA Extraction/Isolation Market  Segmentation (Value)
4   Global cfDNA Extraction/Isolation Volume by Extraction Technology
5   Global cfDNA Extraction/Isolation Share by Extraction Technology, 2016
6   Global cfDNA Extraction/Isolation Share by Extraction Technology, 2026
7   Market Penetration of Automation Systems (Area Represent the Penetration Share), 2016
8   Global cfDNA Extraction/Isolation Market by Application (US$ Mn), 2016-2026
9   Global cfDNA Extraction/Isolation Market by Application, 2016
10   Global cfDNA Extraction/Isolation Market by Application, 2026
11   Global cfDNA Extraction/Isolation Market by Application (US$ Mn)
12   Global cfDNA Extraction/Isolation Market by End-User, 2016
13   Global cfDNA Extraction/Isolation Market by End-User, 2026
14   Global cfDNA Extraction/Isolation Market by Platform/technique (US$ Mn)
15   Global cfDNA Extraction/Isolation Market by Platform/technique, 2016
16   Global cfDNA Extraction/Isolation Market by Platform/technique (US$ Mn), 2026
17   Global cfDNA Extraction/Isolation Market by region, 2016
18   Global cfDNA Extraction/Isolation Market, by Region 2023
19   Global cfDNA Extraction/Isolation Market Growth Rate by Region
20   Global cfDNA Extraction/Isolation Market, 2016-2026 (US$ Mn)
21   Global cfDNA Extraction/Isolation Market, 2016-2026 (Sample processed Volume)
22   Global cfDNA Extraction/Isolation Market by Application ($Million)
23   Global cfDNA Extraction/Isolation Market by Application (Test Volume, Units)
24   Global cfDNA Extraction/Isolation Market ($Million)
25   Total cfDNA Isolation Volume by Major Countries ($Million), 2016 & 2026
26   Global cfDNA Extraction/Isolation Market by Region 2016
27   Global cfDNA Extraction/Isolation Market by Region 2023
28   North America cfDNA Extraction/Isolation Market Growth Pattern, 2016-2026
29   Europe cfDNA Extraction/Isolation Market Growth Pattern, 2016-2027
30   Asia Pacific cfDNA Extraction/Isolation Market Growth Pattern, 2016-2026
31   Latin America cfDNA Extraction/Isolation Market Growth Pattern, 2016-2026
32   Global Research Genomics Market, 2016 (US$ Bn)
33   Global Clinical Genomics Market, 2016 (US$ Bn)
34   Recent Historical Trends 2013-2016 (cfDNA): Prenatal Testing
35   Company/Laboratory Offering cfDNA Test (NIPT and Cancer)
36   cfDNA Based Test Volume, 2011-2026
37   Market Share Analysis, 2015
38   Market Share Analysis, 2016
39   Value Chain
40   Global cfDNA extraction/isolation market: By Product
41   Global cfDNA extraction/Isolation Market by Products ($Million)
42   Global cfDNA Extraction/Isolation Market Share by Product 2016
43   Global cfDNA Extraction/Isolation Market Share by Product 2026
44   Global cfDNA Extraction/Isolation Kits Market ($Million)
45   Global cfDNA Automated Extraction System Market ($Million)
46   Global cfDNA Other Consumables Market ($Million)
47   Global Magnetic bead-based cfDNA Extraction Kits Market ($Million)
48   Global Magnetic bead-based cfDNA Extraction Kits Market (In Thousand Units)
49   Global Column based cfDNA Extraction Kits Market (US$ Mn)
50   Global Column based cfDNA Extraction Kits Market (In Thousand Units)
51   Global Other cfDNA Extraction Kits Market (US$ Mn)
52   Global Other cfDNA Extraction Kits Market (In Thousand Units)
53   Global Automated Instruments cfDNA Extraction System Market ($Million)
54   Global Consumables cfDNA Extraction Market ($Million)
55   Global cfDNA Extraction/Isolation Market ($Million)
56   Global cfDNA Extraction/Isolation Market (Sample Volume, Thousand Units)
57   Global cfDNA Extraction Isolation Market Growth Rate by Revenue
58   Global cfDNA Extraction Isolation Market Growth Rate by Volume
59   Growth Share Matrix by Platform, 2016
60   cfDNA NGS Market, 2016-2026 ($Million)
61   cfDNA NGS Market, 2016-2026 (Test Volume, in Thousand Units)
62   rPCR and Multiplexed PCR Based cfDNA Processing Volume (Thousand Units)
63   rPCR and Multiplexed PCR Based cfDNA Processing Revenue
64   qPCR Based cfDNA Processing Revenue
65   qPCR Based cfDNA Processing Volume (Thousand Units)
66   dPCR Based cfDNA Processing Volume (Thousand Units)
67   dPCR Based cfDNA Processing Revenue
68   cfDNA Quantification Breakdown by Type of PCR, 2016
69   cfDNA Quantification Breakdown by Type of PCR, 2026
70   Global cfDNA Extraction/Isolation Market by Application ($Million)
71   Global cfDNA Extraction/Isolation Market by Application, 2016
72   Global cfDNA Extraction/Isolation Market by Application, 2026
73   Global Oncology cfDNA Extraction/Isolation Market ($Million)
74   Global Oncology cfDNA Extraction/Isolation Market (Test Volume, Thousand Units)
75   Cobas EGFR Mutation Test v2 Volume Growth Projection
76   Global NIPT cfDNA Extraction/Isolation Market ($Million)
77   Global NIPT cfDNA Extraction/Isolation Market (Test Volume, Thousand Units)
78   Global NIPT cfDNA Market Share Analysis (by Test Volume), 2016
79   Global NIPT cfDNA Market Share Analysis (by Test Volume), 2026
80   Growth Share Matrix by cfDNA NIPT Test Providers
81   Global NIPT Market Revenue by Region ($Million)
82   Global NIPT Test Volume by Region (Units)
83   Global Other cfDNA Extraction/Isolation Market ($Million)
84   Global Other cfDNA Extraction/Isolation Market (Test Volume, Thousand Units)
85   Global cfDNA Extraction/Isolation Market by Region, 2016
86   Global cfDNA Extraction/Isolation Market by Region, 2026
87   North America cfDNA Extraction/Isolation Market ($Million)
88   North America cfDNA Extraction/Isolation Market
89   U.S. cfDNA Extraction Kits Market (US$ Mn)
90   U.S. cfDNA Extraction Kits Market (In Thousand Units)
91   Canada cfDNA Extraction Kits Market (US$ Mn)
92   Canada cfDNA Extraction Kits Market (In Thousand Units)
93   U.K. cfDNA Extraction Kits Market ($Million)
94   U.K. cfDNA Extraction Kits Market (In Thousand Units)
95   Germany cfDNA Extraction Kits Market ($Million)
96   Germany cfDNA Extraction Kits Market (In Thousand Units)
97   France cfDNA Extraction Kits Market ($Million)
98   France cfDNA Extraction Kits Market (In Thousand Units)
99   Rest of Europe cfDNA Extraction Kits Market ($Million)
100   Rest of Europe cfDNA Extraction Kits Market (In Thousand Units)
101   Asia Pacific cfDNA Extraction/Isolation Market ($Million)
102   China cfDNA Extraction Kits Market ($Million)
103   China cfDNA Extraction Kits Market (In Thousand Units)
104   Japan cfDNA Extraction Kits Market ($Million)
105   Japan cfDNA Extraction Kits Market (In Thousand Units)
106   India cfDNA Extraction Kits Market ($Million)
107   India cfDNA Extraction Kits Market (In Thousand Units)
108   Agilent Technologies, Inc.: Product Portfolio
109   Agilent Technologies, Inc.: Overall Financials (2014-2016)
110   Agilent Technologies, Inc.: Revenue by Business Segment (2014-2016)
111   Agilent Technologies, Inc.: Revenue by Region (2014-2016)
112   Agilent Technologies, Inc.: SWOT Analysis
113   Berry Genomics: Product Portfolio
114   Berry Genomics: SWOT Analysis
115   BGI Diagnostics: Product Portfolio
116   BGI Diagnostics: SWOT Analysis
117   BioCAT GmbH: Product Portfolio
118   BioCat GmbH: SWOT Analysis
119   F. Hoffmann-La Roche AG: Product/Service Mapping
120   F. Hoffmann-La Roche AG: Net Revenue (2014-2016)
121   F. Hoffmann-La Roche AG: Revenue by Region (2014-2016)
122   F. Hoffmann-La Roche AG: Revenue by Divisions (2014-2016)
123   F. Hoffmann-La Roche AG: : Revenue By Diagnostics Sub-division (2014-2016)
124   F. Hoffmann-La Roche AG: SWOT Analysis
125   GATC Biotech AG: Product Portfolio
126   GATC Biotech AG: SWOT Analysis
127   Illumina, Inc.: Product Portfolio
128   Illumina, Inc.: Overall Financials (2014-2016)
129   Illumina, Inc.: Net revenue, Product revenue and Service revenue (2014-2016)
130   Illumina, Inc.: Revenue by Region, (2014-2016)
131   Illumina, Inc.: SWOT Analysis
132   Laboratory Corporation of America: Product/Service Portfolio
133   Laboratory Corporation of America: Overall Financials (2014-2016)
134   Laboratory Corporation of America: Revenue by Business Segment (2014-2016)
135   Laboratory Corporation of America: Geographic Distribution of Net Revenues (2016)
136   Laboratory Corporation of America: SWOT Analysis
137   LifeCodexx AG: Product Portfolio
138   LifeCodexx AG: SWOT Analysis
139   Merck KGaA: Product/Service Portfolio (Sigma-Aldrich, a Subsidiary of Merck)
140   Merck KGaA: Overall Financials (2014-2016)
141   Merck KGaA: Net Revenue by Business Segments, (2014-2016)
142   Merck KGaA: Revenue by Region (2014-2016)
143   Merck KGaA: SWOT Analysis
144   Natera Inc.: Product/Service Portfolio
145   Natera Inc.: Overall Financials (2014-2016)
146   Natera Inc.: Revenue by Region (2014-2016)
147   Natera Inc.: SWOT Analysis
148   NIPD Genetics: Product Portfolio
149   NIPD Genetics: SWOT Analysis
150   Norgen Biotek Corp.: Product Portfolio
151   Norgen Biotek Corp.: SWOT Analysis
152   PreAnalytiX GmbH: Product Portfolio
153   PreAnalytiX GmbH: SWOT Analysis
154   Premaitha Health Plc: Product Portfolio
155   Premaitha Health Plc: Overall Financials (2014-2016)
156   Premaitha Health Plc: Revenue by Region (2014-2016)
157   Premaitha Health Plc: SWOT Analysis
158   QIAGEN: Product and Service Portfolio
159   QIAGEN: Overall Financials (2014-2016)
160   QIAGEN: Net Revenue by Business Segment (2014-2016)
161   QIAGEN: Net Revenue by Region (2014-2016)
162   QIAGEN: SWOT Analysis
163   Quest Diagnostics: Product Portfolio
164   Quest Diagnostics: Overall Financials (2014-2016)
165   Quest Diagnostics: Revenue by Business Segment (2014-2016)
166   Quest Diagnostics: Revenue by DIS segment (2014-2016)
167   Quest Diagnostics: SWOT Analysis
168   SeraCare Life Sciences, Inc.: Product Portfolio
169   SeraCare Life Sciences, Inc.: SWOT Analysis
170   STRATEC Biomedical AG: Product Portfolio (Stratec Molecular GmbH, a subsidiary of Stratec Biomedical AG)
171   Stratec Biomedical AG: Overall Financials (2014-2016)
172   Stratec Biomedical AG: Revenue by Region (2014-2016)
173   Stratec Biomedical AG: Revenue by Business Segment (2014-2016)
174   Stratec Biomedical AG: Revenue by Business Segment 2014
175   STRATEC Biomedical AG: SWOT Analysis
176   Thermo Fisher Scientific: Overall Financials (2014-2016)
177   Thermo Fisher Scientific: Net Revenue by Business Segment (2014-2016)
178   Thermo Fisher Scientific: Net Revenue by Region (2014-2016)
179   Thermo Fisher Scientific: SWOT Analysis
180   AccuBioMed: Product Portfolio
181   Aline Biosciences: Product Portfolio
182   BioChain: Product Portfolio
183   Bioo Scientific Corporation: Product Portfolio
184   Covaris, Inc.: Product Portfolio
185   Epigentek Group Inc.: Product Portfolio
186   NeoGenStar LLC: Product Portfolio
187   Omega Bio-tek, Inc.: Product Portfolio
188   Promega Corporation: Product Portfolio
189   System Biosciences, LLC: Product Portfolio